Table 3.

Clinical Data on Hodgkin's Patients

Case Class Stage Status at Study Survival (yr)Notes
1  LP  IIIA  1st relapse  16+ Presented @ age 31 → MOPP/DXT → CR → relapse 
2  NS  IIIA  Presentation  2+  LTF  
NS  IIB  Presentation  3+  DXT → CR 
5  NS  IIIB  Presentation  3+ ABVD → CR  
6  NS  IIA  Presentation 3+  DXT → CR  
7  MC  IIA  2nd relapse  7  MOPP → CR → relapse @ 3 yrs → MOPP/ABVD → demised post ABMT 
Case Class Stage Status at Study Survival (yr)Notes
1  LP  IIIA  1st relapse  16+ Presented @ age 31 → MOPP/DXT → CR → relapse 
2  NS  IIIA  Presentation  2+  LTF  
NS  IIB  Presentation  3+  DXT → CR 
5  NS  IIIB  Presentation  3+ ABVD → CR  
6  NS  IIA  Presentation 3+  DXT → CR  
7  MC  IIA  2nd relapse  7  MOPP → CR → relapse @ 3 yrs → MOPP/ABVD → demised post ABMT 

Clinical outcomes of patients involved in this study.

Abbreviations: MOPP, mechlorethamine-oncovin (vincristine)-procarbazine-prednisone; ABVD, Adriamycin-bleomycin-vinblastine-dacarbazine; DXT, deep X-ray therapy; ABMT, autologous bone marrow transplant; CR, complete remission; LTF, lost to follow-up.

Close Modal

or Create an Account

Close Modal
Close Modal